NCT01652781 - 5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

December 31, 2016

Conditions

Myelodysplastic Syndrome

Interventions

DRUG

Azacitidine

5-day arm: azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care 7-day arm: azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care

Trial Locations (3)

137-701

RECRUITING

Seoul St. Mary's Hospital, Seoul

Unknown

RECRUITING

Asan Medical Center, Seoul

RECRUITING

Seoul National University Hospital, Seoul